Core Viewpoint - The announcement reveals that three key shareholders of Kangwei Century (688426.SH) plan to reduce their holdings, which will not significantly impact the company's governance or ongoing operations [1][2]. Shareholder Reduction Plans - Shareholder Zhuang Zhihua intends to reduce up to 21,958 shares, representing 0.0195% of the total share capital - Shareholder Qi Yubai plans to reduce up to 11,311 shares, accounting for 0.0101% of the total share capital - Shareholder Yin Jianfeng aims to reduce up to 9,981 shares, which is 0.0089% of the total share capital - The total reduction by these three shareholders will not exceed 43,250 shares, or 0.0385% of the total share capital, with the reduction period set from February 5, 2026, to May 5, 2026 [1][2]. Shareholding Structure - As of the announcement date, Zhuang Zhihua holds 208,930 shares (0.1857% of total share capital), with 121,098 shares held indirectly through a management consulting partnership and 87,832 shares from a 2021 stock incentive plan - Qi Yubai holds 163,872 shares (0.1457% of total share capital), with 118,625 shares held indirectly and 45,247 shares from the 2021 stock incentive plan - Yin Jianfeng holds 116,818 shares (0.1038% of total share capital), with 76,894 shares held indirectly and 39,924 shares from the 2021 stock incentive plan [2]. Company Listing and Financials - Kangwei Century was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 25, 2022, with an issue price of 48.98 yuan per share and a total of 23,290,278 shares issued, of which 25% were publicly offered - The total funds raised amounted to 1,140.7578 million yuan, with a net amount of 1,054.3036 million yuan after deducting issuance costs, exceeding the original fundraising plan by 68.6277 million yuan - The funds are intended for projects related to medical devices, marketing network construction, molecular detection product R&D, and working capital [3][4].

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. has conducted its second board meeting, approving several key proposals related to its 2025 semi-annual report, fundraising, project completion, and governance changes, reflecting a commitment to transparency and operational efficiency [1][2][3]. Group 1: Financial Reporting and Fund Management - The board approved the 2025 semi-annual report, confirming compliance with relevant laws and regulations, and asserting that the report accurately reflects the company's financial status and operational results [1]. - The board also approved a special report on the storage and use of raised funds, indicating that the funds have been stored in dedicated accounts and used as intended, with no violations reported [2]. - A proposal to permanently supplement working capital with surplus funds from a completed project was approved, with 10,478.54 million yuan being reallocated for this purpose [3]. Group 2: Operational Efficiency and Governance - The company has actively implemented measures from its 2025 quality improvement and efficiency enhancement plan, focusing on core business, customer expansion, and increased R&D investment [4]. - A proposal to cancel the supervisory board and amend the company’s articles of association was approved, transferring supervisory responsibilities to the audit committee of the board [6]. - The board approved the revision and establishment of several internal governance systems to align with updated regulations and improve operational compliance [7]. Group 3: Shareholder Engagement and Future Meetings - The board proposed to hold the first extraordinary general meeting of 2025 on September 15, 2025, to discuss various matters, ensuring shareholder engagement in corporate governance [8]. - The board also approved the appointment of Yin Jianfeng as a member of the audit committee, enhancing the committee's operational capacity [9].